Logo image of MNDR

MOBILE-HEALTH NETWORK SOLUTI (MNDR) Stock Fundamental Analysis

NASDAQ:MNDR - Nasdaq - KYG622641176 - Common Stock - Currency: USD

1.37  +0.03 (+2.24%)

After market: 1.38 +0.01 (+0.73%)

Fundamental Rating

3

Taking everything into account, MNDR scores 3 out of 10 in our fundamental rating. MNDR was compared to 102 industry peers in the Health Care Providers & Services industry. While MNDR seems to be doing ok healthwise, there are quite some concerns on its profitability. MNDR is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MNDR has reported negative net income.
In the past year MNDR has reported a negative cash flow from operations.
MNDR Yearly Net Income VS EBIT VS OCF VS FCFMNDR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

MNDR has a worse Return On Assets (-214.63%) than 96.08% of its industry peers.
MNDR has a worse Return On Equity (-412.24%) than 84.31% of its industry peers.
Industry RankSector Rank
ROA -214.63%
ROE -412.24%
ROIC N/A
ROA(3y)-96.24%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MNDR Yearly ROA, ROE, ROICMNDR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

With a Gross Margin value of 18.18%, MNDR is not doing good in the industry: 63.73% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of MNDR has declined.
MNDR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.09%
GM growth 5YN/A
MNDR Yearly Profit, Operating, Gross MarginsMNDR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -50 -100

More info and screens

6

2. Health

2.1 Basic Checks

MNDR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MNDR has been increased compared to 1 year ago.
MNDR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MNDR Yearly Shares OutstandingMNDR Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M
MNDR Yearly Total Debt VS Total AssetsMNDR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

MNDR has an Altman-Z score of -7.35. This is a bad value and indicates that MNDR is not financially healthy and even has some risk of bankruptcy.
MNDR has a Altman-Z score of -7.35. This is amonst the worse of the industry: MNDR underperforms 88.24% of its industry peers.
MNDR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.35
ROIC/WACCN/A
WACC9.1%
MNDR Yearly LT Debt VS Equity VS FCFMNDR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

A Current Ratio of 2.31 indicates that MNDR has no problem at all paying its short term obligations.
The Current ratio of MNDR (2.31) is better than 78.43% of its industry peers.
A Quick Ratio of 2.26 indicates that MNDR has no problem at all paying its short term obligations.
MNDR's Quick ratio of 2.26 is fine compared to the rest of the industry. MNDR outperforms 78.43% of its industry peers.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 2.26
MNDR Yearly Current Assets VS Current LiabilitesMNDR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

7

3. Growth

3.1 Past

MNDR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -508.64%.
Looking at the last year, MNDR shows a very strong growth in Revenue. The Revenue has grown by 89.75%.
MNDR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 75.52% yearly.
EPS 1Y (TTM)-508.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-493.66%
Revenue 1Y (TTM)89.75%
Revenue growth 3Y75.52%
Revenue growth 5YN/A
Sales Q2Q%77.38%

3.2 Future

The Earnings Per Share is expected to grow by 42.10% on average over the next years. This is a very strong growth
MNDR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 78.77% yearly.
EPS Next Y96.15%
EPS Next 2Y42.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year81.13%
Revenue Next 2Y78.77%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
MNDR Yearly Revenue VS EstimatesMNDR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 10B 20B 30B 40B
MNDR Yearly EPS VS EstimatesMNDR Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MNDR. In the last year negative earnings were reported.
Also next year MNDR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNDR Price Earnings VS Forward Price EarningsMNDR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNDR Per share dataMNDR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

MNDR's earnings are expected to grow with 42.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.1%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MNDR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOBILE-HEALTH NETWORK SOLUTI

NASDAQ:MNDR (5/20/2025, 8:17:49 PM)

After market: 1.38 +0.01 (+0.73%)

1.37

+0.03 (+2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)10-23 2024-10-23
Earnings (Next)N/A N/A
Inst Owners2.21%
Inst Owner Change-7.14%
Ins Owners26.73%
Ins Owner ChangeN/A
Market Cap5.96M
Analysts82.86
Price Target65.28 (4664.96%)
Short Float %8.84%
Short Ratio0.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)700%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.29
P/FCF N/A
P/OCF N/A
P/B 1.44
P/tB 1.45
EV/EBITDA N/A
EPS(TTM)-4.83
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS4.74
BVpS0.95
TBVpS0.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -214.63%
ROE -412.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.18%
FCFM N/A
ROA(3y)-96.24%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.09%
GM growth 5YN/A
F-Score4
Asset Turnover2.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.01%
Cap/Sales 0.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.31
Quick Ratio 2.26
Altman-Z -7.35
F-Score4
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)101.22%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.18%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-508.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-493.66%
EPS Next Y96.15%
EPS Next 2Y42.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)89.75%
Revenue growth 3Y75.52%
Revenue growth 5YN/A
Sales Q2Q%77.38%
Revenue Next Year81.13%
Revenue Next 2Y78.77%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-272.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-168.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-184.86%
OCF growth 3YN/A
OCF growth 5YN/A